MedCity News June 9, 2020
Late last month, Medable and LabCorp CRO Covance signed a deal to accelerate adoption of decentralized trials, a trend that has been helped along as Covid-19 has created challenges to conducting trials dependent on traditional brick-and-mortar sites.
Late last month, one of the largest contract research organizations and its parent company announced a partnership with a technology company to promote adoption of virtual clinical trials. But an important subtext to the trend is what has helped drive it over the past few months: the Covid-19 pandemic.
Burlington, North Carolina-based LabCorp, the lab-testing giant, said May 28 that its CRO, Covance, would partner with Medable, a Palo Alto, California-based company that makes software for digital clinical trials, to give patients access...
Today's Sponsors
Today's Sponsor